BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4
1615 results:

  • 1. VC-resist glioblastoma cell state: vessel co-option as a key driver of chemoradiation resistance.
    Pichol-Thievend C; Anezo O; Pettiwala AM; Bourmeau G; Montagne R; Lyne AM; Guichet PO; Deshors P; Ballestín A; Blanchard B; Reveilles J; Ravi VM; Joseph K; Heiland DH; Julien B; Leboucher S; Besse L; Legoix P; Dingli F; Liva S; Loew D; Giani E; Ribecco V; Furumaya C; Marcos-Kovandzic L; Masliantsev K; Daubon T; Wang L; Diaz AA; Schnell O; Beck J; Servant N; Karayan-Tapon L; Cavalli FMG; Seano G
    Nat Commun; 2024 Apr; 15(1):3602. PubMed ID: 38684700
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. RAPID resistance to BET inhibitors is mediated by fgfr1 in glioblastoma.
    Jermakowicz AM; Kurimchak AM; Johnson KJ; Bourgain-Guglielmetti F; Kaeppeli S; Affer M; Pradhyumnan H; Suter RK; Walters W; Cepero M; Duncan JS; Ayad NG
    Sci Rep; 2024 Apr; 14(1):9284. PubMed ID: 38654040
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A 78-year-old woman with diffuse white matter infiltration and predominant involvement of bilateral temporo-parieto-occipital regions.
    Paoli C; Mc Leer A; Boyer J; Mondot L; Dadone-Montaudié B; Godfraind C; Burel-Vandenbos F
    J Cell Mol Med; 2024 Apr; 28(8):e18245. PubMed ID: 38613356
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases.
    Kibe Y; Ohka F; Aoki K; Yamaguchi J; Motomura K; Ito E; Takeuchi K; Nagata Y; Ito S; Mizutani N; Shiba Y; Maeda S; Nishikawa T; Shimizu H; Saito R
    Acta Neuropathol Commun; 2024 Apr; 12(1):57. PubMed ID: 38605367
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. tumor suppressor role of the complement inhibitor CSMD1 and its role in TNF-induced neuroinflammation in gliomas.
    Tuysuz EC; Mourati E; Rosberg R; Moskal A; Gialeli C; Johansson E; Governa V; Belting M; Pietras A; Blom AM
    J Exp Clin Cancer Res; 2024 Apr; 43(1):98. PubMed ID: 38561856
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
    Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
    J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Focused ultrasound-mediated blood-brain barrier opening is safe and feasible with moderately hypofractionated radiotherapy for brainstem diffuse midline glioma.
    Tazhibi M; McQuillan N; Wei HJ; Gallitto M; Bendau E; Webster Carrion A; Berg X; Kokossis D; Zhang X; Zhang Z; Jan CI; Mintz A; Gartrell RD; Syed HR; Fonseca A; Pavisic J; Szalontay L; Konofagou EE; Zacharoulis S; Wu CC
    J Transl Med; 2024 Mar; 22(1):320. PubMed ID: 38555449
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Immunohistochemical expression of histone modification pattern in adult glioblastoma.
    Archana B; D'Cruze L; Sundaram S; Ramanathan K; Ganesh K
    J Cancer Res Ther; 2024 Jan; 20(1):52-56. PubMed ID: 38554298
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?
    Berthelot C; Huchedé P; Bertrand-Chapel A; Beuriat PA; Leblond P; Castets M
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542334
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
    Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
    Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. High-Grade Astrocytoma with Piloid Features: A Dual Institutional Review of Imaging Findings of a Novel Entity.
    Soni N; Agarwal A; Ajmera P; Mehta P; Gupta V; Vibhute M; Gubbiotti M; Mark IT; Messina SA; Mohan S; Bathla G
    AJNR Am J Neuroradiol; 2024 Apr; 45(4):468-474. PubMed ID: 38485198
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data.
    Ye L; Gu L; Wang Y; Xing H; Li P; Guo X; Wang Y; Ma W
    CNS Neurosci Ther; 2024 Mar; 30(3):e14649. PubMed ID: 38448295
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
    Donev K; Sundararajan V; Johnson D; Balan J; Chambers M; Paulson VA; Scherpelz KP; Abdullaev Z; Quezado M; Cimino PJ; Pratt D; Valerio E; Alves de Castro JV; Carraro DM; Torrezan GT; Wolff BM; Kulikowski LD; Costa FD; Aldape K; Ida CM
    J Neuropathol Exp Neurol; 2024 Apr; 83(5):357-364. PubMed ID: 38447592
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
    Arrillaga-Romany I; Lassman A; McGovern SL; Mueller S; Nabors B; van den Bent M; Vogelbaum MA; Allen JE; Melemed AS; Tarapore RS; Wen PY; Cloughesy T
    Neuro Oncol; 2024 May; 26(Supplement_2):S173-S181. PubMed ID: 38445964
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway.
    Ci M; Zhao G; Li C; Liu R; Hu X; Pan J; Shen Y; Zhang G; Li Y; Zhang L; Liang P; Cui H
    Cell Death Dis; 2024 Mar; 15(3):179. PubMed ID: 38429268
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Midline invasion predicts poor prognosis in diffuse hemispheric glioma, H3 G34-mutant: an individual participant data review.
    Kegoya Y; Otani Y; Inoue Y; Mizuta R; Higaki F; Washio K; Koizumi S; Kurozumi K; Ishida J; Fujii K; Yamamoto N; Tanaka Y; Date I
    J Neurooncol; 2024 Mar; 167(1):201-210. PubMed ID: 38427132
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clinical, qualitative imaging biomarkers, and tumor oxygenation imaging biomarkers for differentiation of midline-located IDH wild-type glioblastomas and H3 K27-altered diffuse midline gliomas in adults.
    Sim Y; Choi SH; Lee N; Park YW; Ahn SS; Chang JH; Kim SH; Lee SK
    Eur J Radiol; 2024 Apr; 173():111384. PubMed ID: 38422610
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Adult epithelioid glioblastoma exhibits an extremely poor prognosis and high frequency of SWI/SNF complex mutation: Insights from a retrospective study.
    Xi S; Jiang S; Li H; Huang Q; Lu J; Zhang X; Li Z; Zeng J
    Int J Cancer; 2024 Jul; 155(1):172-183. PubMed ID: 38411299
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
    Odia Y; Koschmann C; Vitanza NA; de Blank P; Aguilera D; Allen J; Daghistani D; Hall M; Khatib Z; Kline C; MacDonald T; Mueller S; Faison SL; Allen JE; Naderer OJ; Ramage SC; Tarapore RS; McGovern SL; Khatua S; Zaky W; Gardner SL
    Neuro Oncol; 2024 May; 26(Supplement_2):S155-S164. PubMed ID: 38400780
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Clinicopathological analysis of rosette-forming glioneuronal tumors.
    Liu J; Lin F; Sun Y; Liu X
    Diagn Pathol; 2024 Feb; 19(1):39. PubMed ID: 38388383
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 81.